Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pani

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|November 11, 2005
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamideGabriele Murineddu, Stefania Ruiu, Giovanni Loriga, et al.
European Heart Journal|June 27, 2015
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabaseGian Paolo Fadini, Angelo Avogaro, Luca Degli Esposti, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2003
Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptorStefania Ruiu, Gèrard A Pinna, Giorgio Marchese, et al.
Journal of Neuroscience Research|July 30, 2024
Behavioral and transcriptional effects of carnosine in the central ring ganglia of the pond snail Lymnaea stagnalisVeronica Rivi, Giuseppe Caruso, Filippo Caraci, et al.
NPJ Digital Medicine|December 8, 2025
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trialJoseph Geraci, Bessi Qorri, Mike Tsay, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
International Immunopharmacology|March 16, 2025
Unraveling lipopolysaccharide-induced behavioral and molecular effects in Lymnaea stagnalis, an emerging model organism for translational neuroscienceVeronica Rivi, Giovanna Rigillo, Silvia Alboni, et al.
The Journal of Clinical Psychiatry|May 20, 2024
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)Clotilde Guidetti, Sara De Martin, Giulia Serra, et al.
Neuroscience Applied|April 10, 2026
Application of the research domain criteria in early-phase clinical development of transdiagnostic neurotherapeutics: A multidisciplinary perspectiveIgor Magaraggia, Franco Di Cesare, Jordi Alonso, et al.
The Primary Care Companion for CNS Disorders|February 23, 2023
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive DisorderClotilde Guidetti, Giulia Serra, Luca Pani, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|November 11, 2005
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamideGabriele Murineddu, Stefania Ruiu, Giovanni Loriga, et al.
European Heart Journal|June 27, 2015
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabaseGian Paolo Fadini, Angelo Avogaro, Luca Degli Esposti, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2003
Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptorStefania Ruiu, Gèrard A Pinna, Giorgio Marchese, et al.
Journal of Neuroscience Research|July 30, 2024
Behavioral and transcriptional effects of carnosine in the central ring ganglia of the pond snail Lymnaea stagnalisVeronica Rivi, Giuseppe Caruso, Filippo Caraci, et al.
NPJ Digital Medicine|December 8, 2025
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trialJoseph Geraci, Bessi Qorri, Mike Tsay, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
International Immunopharmacology|March 16, 2025
Unraveling lipopolysaccharide-induced behavioral and molecular effects in Lymnaea stagnalis, an emerging model organism for translational neuroscienceVeronica Rivi, Giovanna Rigillo, Silvia Alboni, et al.
The Journal of Clinical Psychiatry|May 20, 2024
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)Clotilde Guidetti, Sara De Martin, Giulia Serra, et al.
Neuroscience Applied|April 10, 2026
Application of the research domain criteria in early-phase clinical development of transdiagnostic neurotherapeutics: A multidisciplinary perspectiveIgor Magaraggia, Franco Di Cesare, Jordi Alonso, et al.
The Primary Care Companion for CNS Disorders|February 23, 2023
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive DisorderClotilde Guidetti, Giulia Serra, Luca Pani, et al.
Pageof 14